Lactoferrin and Nanotechnology: New Insights Into Glioblastoma Therapy
CNS Neuroscience & Therapeutics · 2026-09 · 32 (9)
DOI: 10.1002/cns.71070 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 14.09.2026. Verfasst von Atena Abed und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran. Hauptthemen laut MEDLINE: Lactoferrin, Glioblastoma, Brain Neoplasms, Nanotechnology. Die Arbeit nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim
This review aimed to explore emerging therapeutic strategies for glioblastoma multiforme (GBM) through the integration of lactoferrin (LF) and nanotechnology, emphasizing mechanisms that improve drug delivery across the blood–brain barrier (BBB).
Methods
Published studies on LF‐based nanocarriers and their biological mechanisms were systematically reviewed, focusing on LF's molecular interactions, tumor‐targeting capacity, and the design of nanoscale delivery systems capable of enhancing drug bioavailability and selectivity.
Results
LF, an iron‐binding glycoprotein with antimicrobial, antioxidant, and antitumor properties, can interact with low‐density lipoprotein receptor‐related protein‐1 (LRP1), enabling its transport across the BBB and preferential uptake by glioblastoma cells. Nanocarrier systems incorporating LF improved the solubility, circulation half‐life (typically 2‐ to 5‐fold enhancement compared with free drug), and therapeutic performance of chemotherapeutic agents while minimizing systemic toxicity. Studies demonstrated that LF‐based nanoparticles could induce apoptosis, inhibit tumor growth (with tumor volume reductions ranging from approximately 40% to 70% in orthotopic GBM models), and enhance radiosensitivity in GBM models.
Conclusion
LF provides a promising molecular platform for targeted glioblastoma therapy. When integrated with nanocarrier technologies, it enhances therapeutic efficacy, stability, and safety of anticancer agents. The combined LF–nanocarrier approach represents a rational and innovative strategy for improving treatment outcomes in glioblastoma multiforme.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biotechnology, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran.
- Anatomical Sciences Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.
ORCID-Profile: Atena Abed, Javad Amini Mahabadi
Zitieren
APA
Abed, A., & Mahabadi, J. A. (2026). Lactoferrin and Nanotechnology: New Insights Into Glioblastoma Therapy. CNS Neuroscience & Therapeutics, 32(9). https://doi.org/10.1002/cns.71070
Vancouver
Abed A, Mahabadi JA. Lactoferrin and Nanotechnology: New Insights Into Glioblastoma Therapy. CNS Neuroscience & Therapeutics. 2026;32(9). doi:10.1002/cns.71070
BibTeX
@article{Abed2026,
author = {Abed, Atena and Mahabadi, Javad Amini},
title = {Lactoferrin and Nanotechnology: New Insights Into Glioblastoma Therapy},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {9},
doi = {10.1002/cns.71070}
}
EUVIMED